Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARO-LIPID in biomarker-selected metastatic castration-resistant prostate cancer
ACTRN12624001458527Phase 2Recruiting
- Sponsor
- ANZUP Cancer Trials Group
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide + Opaganib with Darolutamide + Placebo (2 arms). Primary endpoint: 12-month radiographic progression-free survival. Started Jun 2025; status: recruiting.
02
Drugs
darolutamideOpaganib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12624001458527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001458527.